Filing Flows

Filing Flows › Neogen (NEOG) › Q1 FY27

Neogen (NEOG) Q1 FY27 earnings results (first quarter fiscal 2027)

10-Q filed Oct 7, 2026

Neogen (NEOG) reported revenue of $223M for the first quarter fiscal 2027 (Q1 FY27), +7% from a year earlier and -1% from the quarter before. Operating margin was -0.8%, net loss $11.9M (5.3% of revenue).

Revenue$223M
Year over year+7%
Quarter over quarter-1%
Operating margin-0.8%
Net earnings−$11.9M

Neogen, Q1 FY27: revenue $223M (+6% year over year), operating margin -0.8%, net loss $11.9M, operating cash flow $12.9M. The chart follows the revenue to costs, profit and cash.

Q1 FY27AmountQ/QY/Y
Revenue$223M-1%+7%
Operating profit−$1.8M-158%—
Net earnings−$11.9M—-133%
Operating cash flow$12.9M-57%+19%
Free cash flow$4.7M——

What changed

Revenue was $222.8M in Q1 FY27, up 7% year over year and down 1% from the previous quarter. Product was the largest line at 88% of revenue. Product added $11.9M year over year (up 6%), 88% of the total change.

Gross margin was 47.4%, up 1.9 points from Q1 FY26. Operating costs exceeded revenue by $1.8M, an operating margin of -0.8%. Operating expenses fell 3% while revenue rose 7%. The fastest-growing cost line was Research & development (+27%). The quarter ended with a net loss of $11.9M, wider than the previous quarter's $11.3M loss. Net interest and other expense of $13.1M was the main reason.

Operating cash flow was $12.9M (up 19% year over year). Non-cash charges added back $29.1M of depreciation and amortization and $3.1M of share-based compensation. Working capital and other items used $7.4M. After purchases of PPE ($8.2M), free cash flow as the company reports it was $4.7M.

Questions

What was Neogen's revenue in the first quarter fiscal 2027?

Neogen (NEOG) reported revenue of $223M for the first quarter fiscal 2027 (Q1 FY27), +7% from a year earlier and -1% from the quarter before.

Was Neogen profitable in the first quarter fiscal 2027?

Operating loss was $1.8M (-0.8% of revenue) and net loss $11.9M.

Open the interactive Sankey →

Source: Neogen 10-Q on SEC EDGAR.